The U.S. Food and Drug Administration has subtracted a pair of COVID-19 monoclonal antibody treatments from the approved list due to what the agency has deemed “ineffectiveness” against the Omicron variant, which has spread rapidly throughout the U.S. and the world.
Due to Omicron, FDA limiting use of COVID-19 antibody treatments
